Event Agenda

Friday, August 28 – Day 1

7:00 – 7:45 am – Breakfast
7:45 – 8:00 am – Opening Remarks
8:00 – 8:30 am – Overview of Delphi Methodology and Voting Process

Localized Disease (MIBC) Setting

8:30 – 8:55 am – Defining Clinical Response to Systemic Therapy
8:55 – 9:20 am – Systemic Therapy After Response
9:20 – 9:45 am – Local Therapy After Systemic Response
9:45 – 10:10 am – Patient Perspective on Therapy Selection After Systemic Response

Regionally Advanced Node-Positive Disease (N1–N3, M0)

10:10 – 10:35 am – Response Assessment and Systemic Therapy Modulation
10:35 – 11:00 am – Definitive Local Therapy in Node-Positive Disease
11:00 – 11:15 am – Break

Metastatic Urothelial Cancer (M1+) Setting

11:15 – 11:40 am – Defining Systemic Therapy Decisions
11:40 am – 12:05 pm – Role of Local Therapy to Metastatic Sites
12:05 – 12:30 pm – Role of Local Therapy to Primary Tumor Site
12:30 – 1:30 pm – Lunch
1:30 – 4:30 pm – Industry Innovation Forum
6:30 pm – Depart for Dinner

Saturday, August 29 – Day 2

7:00 – 7:45 am – Breakfast
7:45 – 8:30 am – Patient Perspectives Panel & Discussion

Clinical Trial and Translational Science Considerations

8:30 – 8:55 am – Clinical Trial Design and Implementation in the Current Era
8:55 – 9:20 am – Incorporating Translational Approaches
9:20 – 9:45 am – Cost Considerations
9:45 – 10:10 am – PRO Endpoints for Incorporation in Clinical Trials
10:10 – 10:20 am – Break

TURBT Best Practices for Multidisciplinary Bladder Cancer Management

10:20 – 10:45 am – TURBT in the Context of Radiation Therapy
10:45 – 11:10 am – TURBT in the Context of Systemic Therapy
11:10 – 11:35 am – Surgical Technical Considerations
11:35 am – 12:00 pm – Limiting Procedural Toxicity and Optimizing Peri-Operative Care
12:00 – 12:25 pm – Pathology and Translational Priorities in TURBT
12:25 – 1:15 pm – Regulatory Perspectives
1:15 – 2:00 pm – Next Steps, Future Projects, Manuscript Timelines, Boxed Lunch & Departures